FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology and can be used to determine progression of cancer of abdominal cavity organs. For this purpose dynamic examination of patient after surgical treatment is carried out. Change of patient's body composition is determined at the background of nutritive-metabolic therapy 1 time per not less often as 28-30 days by means of bioimpedance analysis. Body weight, index of body weight, fat mass, as well as mass of extracellular liquid are assessed. If body weight, index of body weight decrease and/or fat mass decreases with simultaneous increase of extracellular liquid mass in comparison with the previous results of bioimpedance analysis, progression of cancer of abdominal cavity organs in patient is determined.
EFFECT: method ensures 100% accuracy of early determination of tumour progression in patients before X-ray manifestation, which provides possibility of earlier start of chemo-radiotherapy and prolong patient's life span.
2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING CLINICAL COURSE OF HIGHLY DIFFERENTIATED NEUROENDOCRINE PANCREATIC TUMORS | 2020 |
|
RU2747679C1 |
METHOD OF TREATING LOCALLY ADVANCED STOMACH CANCER WITH HIGH METABOLIC AND PROLIFERATIVE ACTIVITY | 2014 |
|
RU2552289C1 |
METHOD OF DIAGNOSING TREATMENT RESPONSE IN PATIENTS WITH COLORECTAL CANCER LIVER METASTASES | 2022 |
|
RU2800325C1 |
METABOLIC CORRECTION METHOD IN PATIENTS WITH PROTEIN-ENERGY INSUFFICIENCY (PEI) | 2019 |
|
RU2714315C1 |
METHOD FOR CORRECTION OF METABOLIC DISORDERS IN PERSONS OF WORKING AGE WITH INCREASED BODY WEIGHT INDEX (BWT) | 2019 |
|
RU2711540C1 |
METHOD FOR PREDICTION OF RISK OF PROGRESSION OF METASTATIC COLORECTAL CANCER AFTER ANTI-EGFR THERAPY | 2024 |
|
RU2820402C1 |
METHOD OF PREDICTING THE EFFECTIVENESS OF LITHOLYSIS IN CHOLELITHIASIS IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2023 |
|
RU2813033C1 |
METHOD FOR PREOPERATIVE PREDICTION OF THE RISK OF LYMPHATIC METASTASIS IN PATIENTS WITH ENDOMETRIAL CANCER T1 INTERMEDIATE RISK STAGE WITH METABOLIC SYNDROME | 2020 |
|
RU2737130C1 |
METHOD FOR EARLY DIAGNOSIS OF PERITONEAL OVARIAN CANCER RECURRENCE AFTER OPTIMUM CYTOREDUCTIVE SURGERY | 2014 |
|
RU2583114C1 |
METHOD OF TREATING OVARIAN CANCER, VERSIONS OF ITS METASTASIS AND RECURRENCE | 2015 |
|
RU2582939C1 |
Authors
Dates
2014-01-10—Published
2012-07-11—Filed